Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections

American Journal of Health-System Pharmacy

Volumn 69, Issue 21, 2012, Pages 1910-1914

  Heil, Emily L ^a   Daniels, Lindsay M ^b   Long, Dustin M ^c   Rodino, Kyle G ^b   Weber, David J ^d   Miller, Melissa B ^d  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PEPTIDE NUCLEIC ACID;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAM STAINING; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 84868605135     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110604     Document Type: Article

References (9)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39:309-17. (Pubitemid 39050477)
2. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35.
3. Pfaller M, Moet G, Messer S et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011; 49:396-9.
4. Garey K, Rege M, Pai M et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006; 43:25-31. (Pubitemid 43939072)
5. Rigby S, Procop GW, Haase G et al. Fluorescence in situ hybridization with peptide nucleic acid probes for rapid identification of Candida albicans directly from blood culture bottles. J Clin Microbiol. 2002; 40:2182-6. (Pubitemid 34596404)
6. Wilson DA, Joyce MJ, Hall LS et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol. 2005; 43:2909-12. (Pubitemid 40827971)
7. Forrest GN, Mankes K, Jabra-Rizk MA et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol. 2006; 44:3381-3. (Pubitemid 44413783)
8. Alexander BD, Ashley ED, Reller B et al. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis. 2006; 54:277-82.
9. Klutts J, Robinson-Dunn B. A critical appraisal of the role of the clinical microbiology laboratory in diagnosis of invasive fungal infections. J Clin Microbiol. 2011; 49:S39-42.